Application
- Several prospective and retrospective studies showed that targeting the renin-angiotensin system (RAS) may improve cancer treatment.
- In the level of the tumor microenvironment, AT1 blockers were found to affect Cancer-associated fibroblasts (CAFs), which can either inhibit or enable antitumor immunity, suggesting that they may be reprogrammed between these states.
- AT1 blocker drugs can reprogram CAFs to a quiescent state. In addition, AT1 blockers may reduce immunosuppression and improve cancer immunotherapy efficacy.
The activity of AT1 blockers is required to be specific to the target site (tumor, lungs) with minimal effect in the circulation to avoid dangerous hypotension. This target may be achieved using liposomes that will be either administered by injection and passively target the tumor/lungs or administered by inhalation and localized in the lungs. Two AT1 blockers, valsartan and candesartan were evaluated as an example to highly efficient and stable remote loading of AT1 blockers into nano-liposomes exhibiting trans-membrane acetate gradient. Additional AT1 blockers having high protein binding that reduce to very large extent their activity in the circulation is suitable for nano-liposomal delivery and included in this invention.
Our Innovation
Since the activity of AT1 blockers is required to be specific to the target site (tumor, lungs) with minimal effect in the circulation to avoid dangerous hypotension, we develop nano-liposomes, administered by injection and passively target the tumor/lungs or administered by inhalation and localized in the lungs.
Advantages
- Improving cancer treatment with AT1 blocker drugs, administered by injection.
- Avoiding dangerous hypotension since the injection of PEGylated nano-liposomes will be passively concentrated in the tumor site.
- Highly efficient and stable remote loading of AT1 blockers into nano-liposomes exhibiting trans-membrane acetate gradient.
Opportunity
These new formulations, having diverse pharmacological activities, may be the basis for future liposomal drug development.
We are seeking collaboration with pharma companies active in anti-cancer drug development and new formulations.
